Carisma Therapeutics’ (CARM) Buy Rating Reaffirmed at D. Boral Capital

Carisma Therapeutics (NASDAQ:CARM)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $12.00 price target on the stock.

Other equities analysts also recently issued reports about the company. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Finally, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Carisma Therapeutics has a consensus rating of “Hold” and an average price target of $4.94.

Carisma Therapeutics Stock Down 0.6 %

Shares of NASDAQ CARM opened at $0.47 on Monday. The firm has a market capitalization of $19.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.44. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.94. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.93.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Sell-side analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Investors Weigh In On Carisma Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the last quarter. Wexford Capital LP boosted its stake in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Carisma Therapeutics during the 2nd quarter worth about $40,000. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.